Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: Meta-analysis of long-term studies

American Journal of Hypertension

Volumn 28, Issue 3, 2015, Pages 312-318

  Marzano, Luigi ^a   Colussi, Gianluca ^a   Sechi, Leonardo A ^a   Catena, Cristiana ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Adrenalectomy; blood pressure; hyperaldosteronism; hypertension; left ventricular hypertrophy; left ventricular mass; mineralocorticoid receptor antagonists

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

ADRENALECTOMY; ARTICLE; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL (TOPIC); DIASTOLIC BLOOD PRESSURE; FOLLOW UP; HEART LEFT VENTRICLE MASS; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; INTERMETHOD COMPARISON; LONG TERM CARE; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT DURATION; COMPARATIVE STUDY; DRUG EFFECTS; HEART VENTRICLE; ORGAN SIZE; PATHOLOGY;

ADRENALECTOMY; HEART VENTRICLES; HUMANS; HYPERALDOSTERONISM; MINERALOCORTICOID RECEPTOR ANTAGONISTS; ORGAN SIZE;

EID: 84930678831     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpu154     Document Type: Article

References (40)

1. Plouin PF, Amar L, Chatellier G; COMETE-Conn Study Group. Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension. Nephrol Dial Transplant 2004; 19:774-777.
2. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89:1045-1050.
3. Gordon RD. The challenge of more robust and reproducible methodology in screening for primary aldosteronism. J Hypertens 2004; 22:251-255.
4. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141:334-341.
5. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, Porcellati C. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54.
6. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlof B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292:2350-2356.
7. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996; 27:1039-1045.
8. Tanabe A, Naruse M, Naruse K, Hase M, Yoshimoto T, Tanaka M, Seki T, Demura R, Demura H. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hypertens Res 1997; 20:85-90.
9. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi LA. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50:911-918.
10. Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, Mantero F, Pessina AC. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 2013; 62:62-69.
11. Giacchetti G, Ronconi V, Turchi F, Agostinelli L, Mantero F, Rilli S, Boscaro M. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 2007; 25:177-186.
12. Bernini G, Bacca A, Carli V, Carrara D, Materazzi G, Berti P, Miccoli P, Pisano R, Tantardini V, Bernini M, Taddei S. Cardiovascular changes in patients with primary aldosteronism after surgical or medical treatment. J Endocrinol Invest 2012; 35:274-280.
13. Muiesan ML, Salvetti M, Paini A, Agabiti-Rosei C, Monteduro C, Galbassini G, Belotti E, Aggiusti C, Rizzoni D, Castellano M, Agabiti-Rosei E. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008; 52:529-534.
14. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243-1248.
15. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168:80-85.
16. Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, Quinkler M, Hanslik G, Lang K, Hahner S, Allolio B, Meisinger C, Holle R, Beuschlein F, Bidlingmaier M, Endres S. Observational study mortality in treated primary aldosteronism: the German Conn's registry. Hypertension 2012; 60:618-624.
17. Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, Crudo V, Burrello J, Milan A, Rabbia F, Veglio F. Long-term cardio-and cerebro-vascular events in patients with primary aldosteronism. J Clin Endocrinol Metab 2013; 98:4826-4833.
18. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 2013; 62:331-336.
19. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266-3281.
20. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina AC. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997; 95:1471-1478.
21. Yoshitomi Y, Nishikimi T, Abe H, Yoshimar F, Suzuki T, Ashizawa A, Nagata S, Kuramochi M, Matsuoka H, Omae T. Comparison of changes in cardiac structure after treatment in secondary hypertension. Hypertension 1996; 27:319-323.
22. Rizzoni D, Muiesan ML, Porteri E, Salvetti M, Castellano M, Bettoni G, Tiberio G, Giulini SM, Monteduro C, Garavelli G, Agabiti-Rosei E. Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol 1998; 32:985-992.
23. Catena C, Colussi GL, Di Fabio A, Valeri M, Marzano L, Uzzau A, Sechi LA. Mineralocorticoid antagonist treatment versus surgery in primary aldosteronism. Horm Metab Res 2010; 42:440-445.
24. Quinones MA, Otto C, Stoddard M, Waggoner A, Zoghbi W. Recommendations for quantifications of Doppler echocardiography: a report from the Doppler quantification Task Force for the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002; 15:167-184.
25. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rucker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JP. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343:d4002.
26. Sechi LA, Colussi GL, Di Fabio A, Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens 2010; 23:1253-1260.
27. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan D, Sos TA, Atlas SA, Muller FB, Acevedo R, Ulick S, Laragh JH. Diagnosis and treatment of primary aldosteronism. Ann Intern Med 1994; 121:877-885.
28. Sawka AM, Young WF Jr, Thompson GB, Grant CS, Farley DR, Leibson C, van Herdeen JA. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001; 135:258-261.
29. Catena C, Colussi GL, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Relationships of plasma renin levels with renal function in patients with primary aldosteronism. Clin J Am Soc Nephrol 2007;2: 722-731.
30. van der Linden P, Steichen O, Zinzindohoué F, Plouin PF. Blood pressure and medication changes following adrenalectomy for unilateral primary aldosteronism: a follow-up study. J Hypertens 2012; 30:761-769.
31. Zhang X, Zhu Z, Xu T, Shen Z. Factors affecting complete hypertension cure after adrenalectomy for aldosterone-producing adenoma: outcome in a large series. Urol Int 2013; 90:430-434.
32. Rossitto G, Regolisti G, Rossi E, Negro A, Nicoli D, Casali B, Toniato A, Caroccia B, Seccia MT, Walther T, Rossi GP. Elevation of angiotenisn-II type-1-receptor autoantibodies titer in primary aldosteronismas a result of aldosterone-producing adenoma. Hypertension 2013; 61:526-533.
33. Kem DC, Li H, Velarde-Miranda C, Liles C, Vanderlinde-Wood M, Galloway A, Khan M, Zillner C, Benbrook A, Rao V, Gomez-Sanchez CE, Cunningham MW, Yu X. Autoimmune mechanisms activationg the angiotensin AT1 receptor in primary aldosteronism. J Clin Endocrinol Metab 2014; 99:1790-1797.
34. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964; 10:159-172.
35. Catena C, Colussi GL, Marzano L, Sechi LA. Predictive factors of left ventricular mass changes after treatment of primary aldosteronism. Horm Metab Res 2012; 44:188-193.
36. Lin YH, Wang SM, Wu VC, Lee JK, Kuo CC, Yen RF, Liu KL, Huang KH, Chueh SC, Wang WJ, Lin LY, Ho YL, Chen MF, Wu KD. Factors influencing left ventricular mass regression in patients with primary aldosteronism post adrenalectomy. J Renin Angiotensin Aldosterone Syst 2011; 12:48-53.
37. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11-beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995; 92:175-182.
38. Schmidt BMW, Schmieder RE. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens 2003; 16:80-86.
39. Catena C, Colussi G, Marzano L, Sechi LA. Aldosterone and the heart: from basic research to clinical evidence. Horm Metab Res 2012; 44:181-187.
40. Funder JW. Primary aldosteronism: are we missing the wood for the trees. Horm Metab Res 2012; 44:251-253.